The High Throughput Screening (HTS) and Chemical Synthesis (CS) Shared Resource provides state-ofthe- art capability for Vanderbilt-lngram Cancer Center (VICC) researchers to harness the power of HTS/CS to support target discovery, pathway mapping, chemical tool discovery, and exploratory preclinical drug discovery research. HTS/CS includes a chemical library of >170,0000 small molecules, advanced liquid handling, and a broad array of signal detecfion modalifies enabling researchers to address quesfions spanning from protein-protein interactions in purified cell-free systems to colony formation and morphology assays using automated imaging. The facility has the capability of addressing all commonly used opfical techniques (fluorescence, luminscense, kinefic imaging, high-content imaging, scinfillation proximity, refractive index spectroscopy (Corning Epic), automated electrophysiology, and very shortly in collaboration with Stephen Fesik, Ph.D. fragment-based NMR approaches). The complementary CS resource provides an ability to apply advanced chemical synthesis and medicinal chemistry methodologies including solution-phase parallel synthesis, microwave assisted catalysis, automated mass-directed purification, and both chiral synthesis and purificafion resources. HTS/CS employs a highly trained staff of HTS experts who work directly with Vanderbilt investigators to develop, implement, and interpret HTS. This team works hand-in-hand with the team in the CS facility to help investigators extract maximum value from the shared resource by providing a mechanism to use medicinal chemistry techniques to understand, improve, and ufilize HTS hits. David Weaver, Ph.D., directs the HTS component and Alex Waterson, Ph.D., directs the CS portion.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-18
Application #
8733542
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
18
Fiscal Year
2014
Total Cost
$180,339
Indirect Cost
$89,303
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Paul, Pritha; Rellinger, Eric J; Qiao, Jingbo et al. (2017) Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma. Oncotarget 8:82609-82620
Stephenson, Jason R; Wang, Xiaohan; Perfitt, Tyler L et al. (2017) A Novel Human CAMK2A Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and Causes ASD-Related Behaviors. J Neurosci 37:2216-2233
Bouziat, Romain; Hinterleitner, Reinhard; Brown, Judy J et al. (2017) Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 356:44-50
Moyo, T K; Wilson, C S; Moore, D J et al. (2017) Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. Oncogene 36:4653-4661
Vilgelm, Anna E; Cobb, Priscilla; Malikayil, Kiran et al. (2017) MDM2 Antagonists Counteract Drug-Induced DNA Damage. EBioMedicine 24:43-55
LePage, Daniel P; Metcalf, Jason A; Bordenstein, Sarah R et al. (2017) Prophage WO genes recapitulate and enhance Wolbachia-induced cytoplasmic incompatibility. Nature 543:243-247
Li, Jun; Smith, Jarrod A; Dawson, Eric S et al. (2017) Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening. Bioconjug Chem 28:1016-1023
Zhang, Juliet; Weinrich, Jarret A P; Russ, Jeffrey B et al. (2017) A Role for Dystonia-Associated Genes in Spinal GABAergic Interneuron Circuitry. Cell Rep 21:666-678
Aune, T M; Crooke 3rd, P S; Patrick, A E et al. (2017) Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants. J Autoimmun 81:99-109
Esbenshade, Adam J; Zhao, Zhiguo; Aftandilian, Catherine et al. (2017) Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer 123:3781-3790

Showing the most recent 10 out of 2332 publications